Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Zilovertamab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Merck & Co
Deal Size : $2,750.0 million
Deal Type : Acquisition
Details : Acquisition strengthens merck’s oncology pipeline with VLS-101, an investigational antibody-drug conjugate to treat hematological malignancies and solid tumors.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : $2,750.0 million
November 05, 2020
Lead Product(s) : Zilovertamab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Merck & Co
Deal Size : $2,750.0 million
Deal Type : Acquisition
VelosBio Announces First Patient Dosed in Phase 2 Trial of VLS-101 in Solid Tumors
Details : The Phase 2 trial will enroll patients with previously treated solid tumors. Patients will receive VLS-101 2.5 mg/kg intravenously once every three weeks for as long as they are safely benefiting from VLS-101 therapy.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
October 19, 2020
Details : Food and Drug Administration (FDA) has granted the company Fast Track and Orphan Drug designation for VLS-101 for the treatment of patients with mantle cell lymphoma (MCL).
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
August 31, 2020
Details : Oversubscribed funding round to advance the development of investigational, first-in-class antibody-drug conjugates and bispecific antibodies targeting ROR1, a novel oncology target, across multiple cancer types.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
July 08, 2020
Reset All
